Navigation Links
Enrollment for Medicare IVIG Demonstration Project Begins August 8, 2014
Date:8/6/2014

TOWSON, Md., Aug. 6, 2014 /PRNewswire/ -- The Immune Deficiency Foundation (IDF) is pleased to announce that the enrollment for the Medicare IVIG Demonstration Project will begin on August 08, 2014. The enrollment period will end on September 12, 2014, so patients should act quickly to sign up. If approved, a beneficiary receiving an IVIG home infusion after October 01, 2014 will be covered. Medicare will inform all applicants by September 30th of their status.

Patients who are covered under Medicare Fee-For-Service and enrolled in Part B; have a diagnosis of primary immunodeficiency (PI); and are not currently covered under a home health episode of care, are eligible for enrollment. Interested participants should complete, sign and submit an enrollment application to be considered for the demonstration project, and they can do so at http://www.medicarenhic.com.

If enrolled in the IVIG demonstration, Medicare will pay a bundled payment for supplies and related nursing services to administer patients IVIG medication in the home. Participation in the demonstration will not affect any other Medicare benefits, participation is voluntary – and participants can withdraw at any time.

In January 2013, the Medicare IVIG Access Act (HR 1845) was signed into law by President Barack Obama, creating a three-year demonstration project allowing for the payment of home infusion services for Medicare patients with PI.

"IDF strived for years to have the legislation passed that would help cover the costs of home infusion in the Medicare law, and we are thrilled that the demonstration project is beginning," said Marcia Boyle, IDF President & Founder. "Patients with primary immunodeficiency diseases should have the right to access to all sites of care including the right to be infused in the home setting if that is medically appropriate."

The demonstration project should prove the cost effectiveness of allowing Medicare patients with PI access to home infusions of IVIG, thus paving the way for a permanent fix to this issue.

For more information, or to get a copy of the enrollment application, visit http://www.medicarenhic.com, or call (844)-625-6284. Please note that submitting an application for this demonstration does not guarantee that a patient will be selected to participate.


'/>"/>
SOURCE Immune Deficiency Foundation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
2. Verified Clinical Trials Stops Dual Enrollment in Clinical Trials in Major CNS Clinical Trials to Reduce Potential Adverse Events and Improve Data Quality
3. Major CRO Gives Top Ratings To Verified Clinical Trials To Stop Dual Enrollment In Clinical Trials On Late Phase Trial
4. AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
5. Verified Clinical Trials Selected to Prevent Dual Enrollment in Clinical Trials, Will Add Over 800 Additional Sites for a New Phase 3 North American Clinical Trial
6. TrialNetworks Customer to Present Results of Using Site Engagement Technology to Improve Study Operations and Patient Enrollment at Clinical Trial Optimization Conference
7. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
8. Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial
9. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
10. Spaulding Clinical Research Partners With Verified Clinical Trials Protecting Clinical Trials From Dual Enrollment
11. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... Baltimore biotech firm, ... firm, to bring its proprietary CANARY pathogen detection technology and high throughput testing ... firm has purchased an undisclosed number of PathSensors’ Zephyr pathogen detection instruments and ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... will feature Federal Hybrids, Inc. in an upcoming episode, scheduled to broadcast fourth ... Farmer will explore Federal Hybrids, the independent, family-owned seed company. Educating audiences about ...
(Date:8/16/2017)... Prussia, PA (PRWEB) , ... August 16, 2017 , ... ... be taking part in sessions at the ISPE Annual Meeting and Expo , ... Marquis San Diego Marina. The event’s theme is “Driving innovation to advance patient therapies.” ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics ... secured $2M in funding from an impressive group of investors, including Rev1 Ventures, ... Fund. With this investment, 3Bar is broadening availability of its groundbreaking offering that ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):